Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07300150 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 5 → 9 locations Enrollment target: 195 to 210 · Eligibility criteria expanded, about 7 wordsv3 Show 2 more changesShow less
    • Enrollment target: 195 to 210
    • Eligibility criteria expanded, about 7 words

    See this version in full on ClinicalTrials.gov ↗

  2. Site details revised at 3 of 5 sitesv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
PAQ Therapeutics, Inc.
2 trials monitored
See all monitored trials
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
2,932 trials monitored
See 157 trials at risk
Colorectal Cancer
2,920 trials monitored
See 132 trials at risk
and 1 more disease
The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).
Trial Details
NCT Number NCT07300150
Lead Sponsor PAQ Therapeutics, Inc.
Conditions Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
Enrollment 210 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov